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Hospital-based Surveillance Provides Insights Into the 
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Background.  Meningitis is endemic to regions of Cameroon outside the meningitis belt including the capital city, Yaoundé. 
Through surveillance, we studied the etiology and molecular epidemiology of pediatric bacterial meningitis in Yaoundé from 2010 
to 2016.
Methods. Lumbar puncture was performed on 5958 suspected meningitis cases; 765 specimens were further tested by cul-
ture, latex agglutination, and/or polymerase chain reaction (PCR). Serotyping/grouping, antimicrobial susceptibility testing, and/or 
whole genome sequencing were performed where applicable.
Results. The leading pathogens detected among the 126 confirmed cases were Streptococcus pneumoniae (93 [73.8%]), 
Haemophilus influenzae (18 [14.3%]), and Neisseria meningitidis (15 [11.9%]). We identified more vaccine serotypes (19 [61%]) than 
nonvaccine serotypes (12 [39%]); however, in the latter years non–pneumococcal conjugate vaccine serotypes were more common. 
Whole genome data on 29 S. pneumoniae isolates identified related strains (<30 single-nucleotide polymorphism difference). All but 
1 of the genomes harbored a resistance genotype to at least 1 antibiotic, and vaccine serotypes harbored more resistance genes than 
nonvaccine serotypes (P < .05). Of 9 cases of H. influenzae, 8 were type b (Hib) and 1 was type f. However, the cases of Hib were ei-
ther in unvaccinated individuals or children who had not yet received all 3 doses. We were unable to serogroup the N. meningitidis 
cases by PCR.
Conclusions. Streptococcus pneumoniae remains a leading cause of pediatric bacterial meningitis, and nonvaccine serotypes may 
play a bigger role in disease etiology in the postvaccine era. There is evidence of Hib disease among children in Cameroon, which 
warrants further investigation.
Keywords. pediatric bacterial meningitis; conjugate vaccine; genotyping.
Bacterial meningitis causes serious illness in children, which 
can lead to death and permanent neurological sequelae in sur-
vivors [1]. Meningitis is endemic to regions of Cameroon that lie 
outside the meningitis belt, including the capital city, Yaoundé. 
A study conducted in Yaoundé between 1999 and 2000 found 
that the majority of bacterial meningitis cases were due to 
Streptococcus pneumoniae (56.2%), Haemophilus influenzae 
(18.5%), and Neisseria meningitidis (13.4%) and noted that 
children aged <5 years were the most vulnerable age group [2]. 
In 2013, Nguefack and colleagues carried out a study at the 
Yaoundé Gyneco-obstetric and Pediatric Hospital to investigate 
the etiology and outcomes of children with purulent meningitis 
[3]. Their study enrolled 171 children aged <15 years with con-
firmed bacterial meningitis by culture or antigen test, most of 
whom were <5 years of age (141 [82.5%]). More than 10 spe-
cies were reported to cause meningitis, the leading causes being 
H. influenzae in 67 children (39.2%), followed by S. pneumoniae 
in 54 children (31.6%) and N. meningitidis in 17 children (9.9%) 
[3]. A high number of deaths and neurological sequelae were 
reported: 32 deaths (18.7%) and 17 cases of sequelae (9.9%) [3].
In the past decade, important vaccine interventions have tar-
geted the main pathogens causing meningitis in Cameroon. The 
H. influenzae type b (Hib) conjugate vaccine was introduced in 
2009 and since then the coverage has remained >80% [4]. In 
2011, the 13-valent pneumococcal conjugate vaccine (PCV13) 
was introduced into the Cameroon Expanded Programme on 
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Immunization. Although the estimated coverage of children 
immunized with PCV13 was low (23%) in 2011, it rose to 85% 
in subsequent years. In December 2011, Cameroon became 
the fourth country in the meningitis belt to roll out the me-
ningococcal A conjugate vaccine (MenAfriVac), which targets 
N.  meningitidis serogroup A, on a large scale. The efficacy of 
PCV13, Hib vaccine, and MenAfriVac in reducing the burden 
of disease in resource-poor settings is well documented [5–9]. 
However, in Cameroon little is known about how the etiology 
of pediatric bacterial meningitis (PBM) has changed, if at all, 
following these interventions.
Whole genome sequencing (WGS) has emerged as a powerful 
tool for genotyping and tracking the evolution of pathogenic 
bacteria. By comparing genome sequences to curated databases, 
we can scan for known antibiotic resistance and virulence geno-
types. Incorporating genomic data into ongoing surveillance 
allows early detection of emerging virulent clones that can po-
tentially lead to meningitis outbreaks [10]. WGS allows us to 
discriminate between genotypes within the same serotype and 
provide insights into the evolution of bacterial pathogens [5].
In 2002, the World Health Organization (WHO) set up the 
global surveillance network for invasive bacterial vaccine-
preventable diseases (IB-VPD), to accurately describe the burden 
and epidemiology of IB-VPD and to assess the impact of vac-
cines on disease burden and epidemiology, particularly the Hib 
vaccine and pneumococcal conjugate vaccines [6]. The WHO 
Collaborating Centre (CC) for New Vaccines Surveillance, hosted 
at the Medical Research Council Unit The Gambia (MRCG), 
supports the IB-VPD surveillance network for West and Central 
Africa in 10 countries including Cameroon.
Here, we present findings on the etiology and molecular ep-
idemiology of meningitis in Cameroon’s capital city from 2010 
through 2016. We assessed the temporal changes in the patho-
gens detected from suspected cases of meningitis and used 
molecular techniques to further describe their epidemiology 
including WGS on a subset of S. pneumoniae isolates.
METHODS
Study Site
Bacterial meningitis surveillance is ongoing at the Centre 
Mere et Enfant de la Fondation Chantal Biya (CME) hospital, 
Yaoundé, which is approximately 600 km south of the men-
ingitis belt. The CME is a specialist hospital that serves as the 
main pediatric referral hospital in Cameroon. Yaounde has an 
equatorial rain forest climate and is not adversely affected by the 
harmattan winds that prevail in the dry season.
Patients
This surveillance was conducted among children <5 years old. 
Suspected meningitis was defined as sudden onset of fever 
(>38.5°C rectal or 38.0°C axillary) accompanied by 1 or more 
of the following symptoms: neck stiffness, altered conscious-
ness, or hypersensitivity to light. Demographic data including 
age, sex, region of residence, vaccination history, and prior an-
tibiotic use was recorded on a case investigation form. Clinical 
information regarding admission date, diagnosis, outcome, 
comorbidities, and sequelae was also recorded.
Study Specimens
Unless clinically contraindicated, cerebrospinal fluid (CSF) 
specimens were collected from children enrolled in the surveil-
lance. Each specimen was linked to a case investigation form 
by a unique identification number. CSF specimens were visu-
ally inspected and the appearance of the CSF specimens was 
recorded. Serological tests including white blood cell (WBC) 
counts and biochemical tests for glucose and protein levels were 
also performed when available [7]. Suspected cases were classi-
fied as probable if the CSF was positive from Gram stain and/
or appeared turbid or had a WBC count >100 cells/μL, or if the 
WBC count ranged between 10 and 100 cells/μL and CSF pro-
tein was >100 mg/dL or if the WBC count ranged between 10 
and 100 cells/μL and CSF glucose was >40 mg/dL. Meningitis 
cases (n = 126) were confirmed for CSF specimens that had a 
pathogen detected by culture, rapid diagnostic test (Pastorex or 
Binax), or real-time polymerase chain reaction (PCR).
Pathogen detection by culture, latex agglutination, and/or 
PCR was performed on CSF from 765 suspected cases of men-
ingitis. At the sentinel site in Yaoundé, 555 samples were tested 
by culture and/or latex: culture was performed on 500 (8.4%) 
suspected cases, whereas rapid testing was done using the 
Pastorex kit on 304 (5.1%) suspected cases. A total of 344 CSF 
specimens were sent to the WHO CC for pathogen detection 
and where possible, serotyping or serogrouping using quantita-
tive PCR (qPCR).
Molecular Characterization at WHO Collaborating Centre
Where sufficient volumes were available, CSF specimens were 
sent to the WHO CC hosted at MRCG for molecular charac-
terization using PCR. In 2011 and 2012, only culture-negative 
CSF specimens were sent to the WHO CC for PCR; how-
ever, between 2013 and 2016 all categories of CSF specimens 
were sent to the WHO CC. During this period, 35 isolates of 
S.  pneumoniae were sent to the WHO CC, based on availa-
bility and viability, and WGS was successfully performed on 29 
isolates.
In brief, DNA was extracted from the CSF using a modified 
Qiagen extraction method as previously described [10]. A qPCR 
assay was used to detect the 3 main pathogens, S. pneumoniae, 
N. meningitidis, and H. influenzae targeting the lytA, sodC, and 
hpd genes, respectively. Serogrouping for N.  meningitidis and 
H.  influenzae was performed by qPCR for targeted serotype-
specific genes as previously described [8]. Streptococcus 
pneumoniae serotyping was performed by subjecting samples 
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to serial triplex PCR assays targeting 21 of the most common 
serotypes globally as previously described [9].
Antimicrobial Susceptibility Testing and WGS
Isolates received at the WHO CC were subcultured onto gen-
tamicin blood agar and cultured overnight at 37°C. Isolates 
were tested for susceptibility to the following antibiotics 
using the disk diffusion method, and inhibition zones were 
interpreted according to Clinical and Laboratory Standards 
Institute guidelines [11]: rifampicin, erythromycin, ceftriaxone/
cefotaxime, tetracycline, vancomycin, oxacillin, chloram-
phenicol, trimethoprim-sulfamethoxazole, meropenem, and 
clindamycin.
Genomic DNA was extracted from fresh overnight cul-
tures using a modified Qiagen kit protocol [10] and sent to the 
Wellcome Trust Sanger Institute for paired-end sequencing on 
an Illumina HiSeq [12]. Sequencing reads from each isolate 
were mapped onto the S. pneumoniae ATCC 700669 serotype 
23F reference genome using SMALT [13], and pseudogenomes 
were placed in a multiple sequence alignment using custom 
scripts. Single-nucleotide polymorphisms (SNPs) were called 
from the pseudoalignment using SNP-sites, and a maximum 
likelihood phylogeny was reconstructed with a general time-
reversible model using RAxML [14]. The phylogenetic tree was 
visualized and annotated using iTOL [15]. ARIBA was used to 
scan the genome for known resistance mutations and virulence 
Table 1. Summary of Patient Information for All Children Admitted With 
Suspected Meningitis, 2010–2016
Characteristic n (%)
Age, mo
 0–11 3702 (62)
 12–23 912 (15)
 24–59 1343 (23)
 Unknown 1 (0)
Sex   
 Male 3326 (56)
 Female 2632 (44)
Antibiotic before admission
 Yes 667 (11)
 No 4889 (82)
 Unknown 402 (7)
Case typea
 Suspected 5832 (98)
 Confirmed 126 (2)
CSF appearance
 Clear 4165 (70)
 Turbid 263 (4)
 Xanthrochromic 824 (14)
 Other 706 (12)
CSF WBC count, cells/μL
 <10 5235 (88)
 10–100 490 (8)
 >100 231 (4)
 Unknown 2 (0)
Abbreviations: CSF, cerebrospinal fluid; WBC, white blood cell.
aSuspected cases include cases that were defined as probable as per World Health 
Organization case definition guidelines [17]. 
Table 2.   Patient Age and Sex for the Specimens That Were Tested by 
Each of the 3 Bacteriological Methods
Characteristic Culture PCR Latex
Sex    
 Female 214 (43) 140 (41) 130 (43)
 Male 286 (57) 204 (59) 173 (57)
Age group, mo    
 0–11 344 (69) 218 (63) 212 (70)
 12–23 66 (13) 49 (14) 38 (13)
 24–59 90 (18) 77 (23) 53 (17)
Data are presented as No. (%). 
Abbreviation: PCR, polymerase chain reaction.
Figure 1. Flowchart summarizing the number of patients, how many had speci-
mens tested by each of the 3 bacteriological methods, and the outcome of the tests. 
Abbreviation: PCR, polymerase chain reaction.
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genes [16]. We analyzed of 29 S. pneumoniae genomes isolated 
from confirmed meningitis cases.
Ethical considerations
Ethical approval was not a requirement in Cameroon for 
routine meningitis surveillance, including drug susceptibility 
testing of collected isolates, as surveillance is part of the ap-
proved routine diagnostic algorithm at the Ministry of Health. 
However, informed consent was sought from the parents or 
guardians of the surveillance participants. Additionally, the sur-
veillance received overarching ethical approval (SCC1188) by 
the joint Medical Research Council (MRC)/The Gambia gov-
ernment ethics board that allowed the analysis of collected West 
African isolates at MRCG.
RESULTS
Patient Characteristics
A total of 5958 children <5 years of age with suspected cases of 
meningitis were recruited into the surveillance from the sen-
tinel site in Yaoundé between 2010 and 2016. Nearly two-thirds 
of the patients admitted were in their first year of life and more 
than half were male (Table 1). The outcome at discharge was 
recorded for 2940 patients, and 141 (4.8%) were confirmed to 
have died before discharge. Lumbar puncture was performed by 
clinicians on all suspected cases to collect CSF. Most CSF sam-
ples (4165 [69.9%]) had clear appearance and WBC count <10 
cells/μL (Table 1). 
Trends in Pathogen Detection by Culture, Rapid Test, and PCR Over Time
Subsets of the specimens were tested using culture, rapid 
tests, and/or PCR (Table 2), and we confirmed a total of 126 
(16.5%) cases of bacterial meningitis. The leading pathogen 
detected among the 126 confirmed cases was S.  pneumoniae 
(93 [73.8%]), followed by H.  influenzae (18 [14.3%]) and 
N. meningitidis (15 [11.9%]) (Figure 1). Among 93 confirmed 
cases of S. pneumoniae meningitis, data on pneumococcal vacci-
nation history were retrieved from the vaccination card or med-
ical records of 35 (37.6%) infants; in most cases (54 [58.1%]), 
data were acquired through oral attestation and in 4 cases there 
was no record. Only 20 (21.5%) infants had confirmed receiving 
the pneumococcal conjugate vaccine, 54 (58%) did not report 
receiving the vaccine, and the vaccination history of 19 (20.5%) 
patients was unknown. Among the cases of S. pneumoniae men-
ingitis that were vaccinated, 6 cases (30%) were associated with 
PCV13 serotypes.
Over time, the proportion of cases that was attributed to 
each of the 3 main pathogens varied. Between 2010 and 2015, 
S. pneumoniae represented at least 60% of all positive cases of 
bacterial meningitis, but this dropped to <50% in 2016. The 
proportion of cases due to H. influenzae was low up to 2015 but 
increased in 2016. This was due to a slight increase in the case 
count of H. influenzae and a sudden decrease in S. pneumoniae 
cases in 2016 (Figure 2). Low numbers of N. meningitidis cases 
were found between 2012 and 2015, but there were no con-
firmed cases of N. meningitidis meningitis in 2016.
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Figure 2. Bar chart showing the proportion of cases due to the 3 vaccine-preventable pathogens detected by a combination of culture, rapid tests, and polymerase chain 
reaction. Secondary axis shows the total number of patients recruited in each year. The Haemophilus influenzae type B vaccine was introduced in 2009 and the 13-valent 
pneumococcal conjugate vaccine was introduced in 2011.
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Molecular Characterization of Etiology and Serotyping
The number of cases of S. pneumoniae detected by PCR fluc-
tuated between 2011 and 2016. Using qPCR, we successfully 
serotyped 31 of 36 S.  pneumoniae isolates that were detected 
by PCR. Between 2011 and 2016, PCR serotyping confirmed 
19 and 12 cases of meningitis associated with PCV13 and non-
PCV13 serotypes, respectively (Figure 3A). The numbers were 
generally low, but from 2013 to 2016 the proportions of non-
PCV13 serotypes increased marginally (Figure 3B and 3C).
Nine H.  influenzae strains were confirmed by PCR and 
typed by qPCR, of which 8 were Hib and 1 was type f. Among 
8 patients that had Hib detected in their CSF, 1 had an un-
known vaccination history, 5 were not vaccinated, and 2 were 
vaccinated but had not completed the full 3-dose regimen: 1 
patient had received 1 dose and 1 had received 2 doses of the 
vaccine. Both patients were females admitted with suspected 
meningitis in 2014 aged 2 and 4  months old, respectively. 
The 2 cases of N. meningitidis detected by PCR could not be 
serogrouped by qPCR.
Whole Genome Phylogeny of S. pneumoniae
The phylogeny of the S.  pneumoniae isolates unearthed ex-
amples of strains that were very similar to one another (<30 SNP 
difference), as shown by the flat branches in the tree (Figure 4). 
This was more common with vaccine serotypes such as 5, 6B, 
14, and 23F, but was also seen in the nonvaccine serotype 33F. 
In all cases, the similar strains both caused meningitis in the 
same year. For example, the 4 serotype 5 isolates, which were 
all ST289, formed 2 subclades, each with 2 isolates. The 2 iso-
lates from 2013 differed by 19 core genome SNPs, whereas the 
2 from 2015 differed by 15 core genome SNPs. In the genome-
sequenced subset, between 2011 and 2013 the proportion of 
nonvaccine serotypes was 28% compared with 73% in 2015 and 
2016 (Figure 3C).
Phenotypic resistance to chloramphenicol (n  =  4 [13.8%]), 
trimethoprim-sulfamethoxazole (n = 10 [34.5%]), tetracycline 
(n = 10 [34.5%], plus 1 intermediate resistance), and oxacillin 
(n = 4 [13.8%]) was shown, and 1 isolate showed intermediate 
resistance to erythromycin. The WGS analysis revealed resist-
ance genotypes in isolates that were classed as sensitive by disk 
diffusion. All but 1 of our isolates harbored a resistance gen-
otype to at least 1 antibiotic. No known virulence genes were 
found by ARIBA in this dataset.
Interestingly, isolates collected between 2011 and 2013 had 
on average a higher number of resistance genotypes per ge-
nome (2.3) compared with isolates collected in 2015 and 
2016, which averaged 1.5 per genome. Similarly, nonvaccine 
serotypes averaged a significantly lower number of resistance 
genes—on average, 1.5 resistance genotypes per genome com-
pared with 2.4 per genome in vaccine serotypes (unpaired t test: 
P = .0212, difference of means [nonvaccine type – vaccine type], 
–0.9135 ± 0.3733 [95% confidence interval, –1.679 to –.1476]) 
(Figure 4B). This was exemplified by serotype 5 where the 2013 
genomes bore 3 resistance genotypes to chloramphenicol, tri-
methoprim, and tetracycline, but the 2015 genomes only had 
the trimethoprim resistance genotype. Vaccines serotypes such 
as 6B and 14 from 2012 also bore at least 3 resistance genotypes.
DISCUSSION
Meningitis continues to be a cause of serious illness and death 
among children in Cameroon, and we show that vaccine-
preventable forms of the disease continue to play a role. Despite 
Figure 3. Distribution of the 13-valent pneumococcal conjugate vaccine (PCV13) 
and non-PCV13 serotypes over the surveillance period. A, Boxplot comparing the 
overall case counts of PCV13 and non–pneumococcal conjugate vaccine (PCV) sero-
types based on the per annum counts. B, Stacked bar chart comparing the case 
counts per annum for PCV13 serotypes and non-PCV13 serotypes. C, Line graph of 
the proportion of PCV serotypes over time (years) with a nonlinear regression line 
of best fit.
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the introduction of PCV13, our study highlighted S. pneumoniae 
as the main etiologic pathogen causing PBM in Yaoundé. The 
low numbers in the study prevent us from drawing definitive 
conclusions on the effect of PCV13. However, both the PCR 
and genomics data showed early signs that nonvaccine sero-
types may expand and play a more important role in causing 
disease in the post-PCV13 era. This phenomenon, known com-
monly as serotype replacement, is a common occurrence that 
follows introduction of conjugate vaccines [18–21]. Our geno-
mics dataset further suggests that the expansion of nonvaccine 
serotypes may be accompanied by a welcome decline in the 
prevalence of antibiotic resistance genotypes borne within the 
S.  pneumoniae genomes. Vaccines have been proposed as a 
means of decreasing antibiotic resistance, but it is too early to 
tell whether that may be the case in Cameroon [22–24].
Annually, the number of confirmed cases of H. influenzae 
and N. meningitidis remained low throughout the study pe-
riod. Half of the H. influenzae cases were serotyped, and al-
most all were Hib. The confirmed cases of Hib were linked 
to either unvaccinated individuals or individuals who were 
yet to complete the full course of 3 vaccine doses. This high-
lights the importance of ensuring full coverage of the Hib 
vaccine among young children, but also raises concerns re-
garding the vulnerability of young infants who have not been 
fully vaccinated with all 3 doses of the Hib vaccine. Generally 
the introduction of the Hib vaccine in low-resource settings 
of Africa and Asia has proven to be an effective means to 
reduce the burden of Hib invasive disease among children 
<5 years of age [25, 26].
Neisseria meningitis has been known to cause menin-
gitis in Cameroon for a long time. Outbreaks of meningitis 
have been caused by N. meningitidis serogroup A in the past 
[27, 28]. Moreover, around the year 2000 there was a surge 
in N.  meningitidis meningitis cases due to an increase in 
serogroup A  and the emergence of serogroup W135 [29]. 
Unfortunately, we were not able to serotype the N. meningitidis 
meningitis cases in our study, so we could not compare our re-
sults to past trends.
VT NVT
Figure 4. A, Maximum likelihood whole genome phylogenetic tree of Streptococcus pneumoniae isolates recovered from cerebrospinal fluid. B, Column graph comparing 
the number of resistance genotypes per genome among vaccine serotypes (VT) and nonvaccine serotypes (NVT). In the phylogeny, the serotypes in blue are nonvaccine types 
and black are vaccine types; earlier years are shaded in a brighter shade of green; resistance/intermediate resistance to chloramphenicol (C), trimethoprim-sulfamethoxazole 
(SXT), tetracycline (TE), oxacillin (OX), and erythromycin (E) is shown by a red box; and the presence of the antibiotic resistance genes catQ (chloramphenicol), folA/ folP (tri-
methoprim), tetM (tetracycline), penicillin-binding proteins (PBP; penicillin), and mef (erythromycin) is shown by a black circle. Blanks mean no data or not tested. Reference 
genome is shown on the tree branch with dashed line.
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Our analysis provides baseline information into the ge-
nomic epidemiology of S. pneumoniae causing pediatric men-
ingitis in Yaoundé and provides insights into the phylogeny of 
S.  pneumoniae in this setting. The small size of the genomic 
dataset makes it difficult to infer definitive trends. Improved 
microbiology protocols and practices may improve isolate re-
covery rates and allow us to generate a more representative ge-
nomic dataset. Concerted efforts need to be made to ensure that 
children are adequately protected from PBM in Cameroon and 
in other low-income settings where the disease is endemic.
There were limitations to this study. In 2010 and 2011, the 
earlier years of surveillance, the patient recruitment was com-
paratively low. The surveillance team worked together to im-
prove case reporting, reflected by a subsequent increase in 
patient recruitment. Moreover, the ratio of samples collected vs 
the number of samples tested was low: Only 765 (12.8%) sam-
ples collected were tested for pathogen detection. The number 
of unknowns regarding sequelae and treatment outcome was 
high and the form of sequelae was not recorded, making it 
difficult to study the long-term adverse effect of meningitis in 
infants.
CONCLUSIONS
We present findings on the etiology of PBM in Yaoundé, 
Cameroon. Streptococcus pneumoniae remains a leading cause 
of meningitis in Yaoundé among children <5 years of age. The 
annual case counts of H.  influenzae and N. meningitidis were 
low during the study period. Our data demonstrate the added 
value of PCR techniques for pathogen detection and molecular 
serotyping/serogrouping.
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